Dubai, UAE, October 7, 2024
Circular Protocol, a Layer 1 blockchain platform, announces the appointment of Dr. Marwan Alzarouni, CEO of the Dubai Blockchain Center (DBCC) and a renowned international blockchain advocate, as a strategic advisor and shareholder.
Dr. Alzarouni’s expertise and leadership in blockchain technology will play a strategic role in advancing Circular Protocol’s mission to revolutionize decentralized solutions.
Dubai Blockchain Center is a strategic partner of the Dubai Future Foundation, that aims to create a thriving ecosystem for blockchain companies in Gulf markets and globally, and it will support the revolutionary blockchain project through its next stages of growth. This comes after Circular Protocol’s successful and rapid pre-seed round, led by several healthcare enterprises.
Leveraging his expertise and network, Dr. Alzarouni will play a pivotal role in shaping the product roadmap and solutions that will enable both private and public enterprises to rethink business and innovation through the power of blockchain and digital assets. Circular Protocol is particularly active in the field of DeSci (Decentralized Science), with a mission to enhance efficiencies and impact within a broad spectrum of applied sciences and healthcare industries.
Dr. Gianluca De Novi, Founder and CEO of Circular Protocol, said: “We are thrilled and honored to have Dr. Alzarouni join the team. His extensive knowledge of blockchain technologies, network, and insights will guide us as we pursue our ambitious growth plans. Our goal is to build a global community of developers, enterprises, and supporters, united in the effort to liberate resources and push the boundaries of DeSci.
We aim to create a future where maximized efficiencies, innovation, and impact flourish, all while safeguarding the interests and privacy of stakeholders. Dr. Alzarouni will also assist us in communicating Circular Protocol’s unique infrastructure to the world. His addition to the team marks the culmination of two years of hard work and strategic planning. We have many exciting developments in the pipeline, and we’ll be sharing more soon.”
Dr. Alzarouni commented: “I am excited to join the innovative Circular Protocol, which is led with vision and determination by Dr. De Novi and his team. The tech stack, strategy, and the quality of people at Circular have convinced me of the immense potential of this new architecture. I am pleased that we share a common goal of shaping a future driven by exponential technologies and strong values. I look forward to embarking on this new journey.”
To learn more, visit: https://circularlabs.io
About Circular Protocol. Circular is a 4th-generation Layer 1 blockchain, designed to address the limitations of previous generation Layer 1 chains. Circular’s primary focus is DeSci, where developers and enterprises can advance research, innovation, and in-market execution across healthcare, pharma, and scientific industries, promoting transparency, data security, and democratized access and ownership.
Circular Protocol provides tamper-proof data auditing via decentralized blockchains and zero-knowledge proofs, ensuring compliance, protecting patient data, and certifying processes and content. With privacy, decentralization, maximum throughput, scalability, interoperability, and proof of reputation, Circular’s proprietary parallelized, multi-chain architecture delivers revolutionary tools and applications.
Circular has offices in Boston and Lugano. Its CEO and Founder, Dr. Gianluca De Novi, is an expert in high-performance computing with a background in 3D real-time graphics, physics simulation, robotics, and blockchain technology. He holds a Master’s in Electronics and Computer Science and a PhD in Robotics from the University of Bologna. Currently, he directs the Medical Device and Simulation Lab at Massachusetts General Hospital and has been a faculty member at Harvard Medical School and Harvard Extension School since 2011. His work includes approximately 15 years of research funded by the US Department of Defense in the MedTech industry.